FOUNDATIONS OF HUMAN BIOLOGY

SMALL LITERATURE GROUP

List of References
September 8, 2014:
First paper and commentary:
FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to
prevent high-grade cervical lesions. NEJM 356: 1915-1927 (2007).
Finn, O.J., and R. P. Edwards. Human Papillomavirus Vaccine for Cancer
Prevention. NEJM 361: 1899-1901 (2009).
Second paper and commentary:
Fong, P.C. et al. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA
Mutation Carriers. NEJM 361: 123-134 (2009).
Editorial: Iglehart, J.D., and D. P. Silver. Synthetic Lethality A New Direction
in Cancer-Drug Development. NEJM 361: 189-191 (2009).
September 15, 2014:
First paper and commentary:
Baselga, J., et al, Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast
Cancer, NEJM 366: 109 (2012)
EXCERPT from an Extension of Survival Analysis for Baselga et al: Swain, S.M. et al,
Overall Survival Benefit with Pertuzumab, Trastuzumab, and Docetaxel for HER2-
Positive Metastatic Breast Cancer in CLEOPATRA, a Ransomised Phase 3 Study,
Lancet Oncology 14: 461 (2013) (First 3 paragraphs of Results, plus Figure 2,
demonstrate the statistical significance of the Overall Survival results with the three-drug
cocktail.)
Editorial: Gradishar, W.J., HER2 Therapy - - An Abundance of Riches, NEJM
366:176 (2012).
Second paper and commentary:
Chapman, P.B., et al, Improved Survival with Vemurafenib in melanoma with BRAF
V600E Mutation, NEJM 364:2507 (2011).

Editorial for a previous, related paper: Smalley, K.S.M, and Sondak, V.K.,
Melanoma An Unlikely Poster Child for Personalized Cancer Therapy,
NEJM 363:876 (2010).
Editorial: Ernstoff, M.S., Been There, not Done That Melanoma in the Age of
Molecular Therapy, NEJM 364:2547 (2011).